文献速递心力衰竭与心肌病

心力衰竭中的贫血与铁缺乏:当前概念与新兴治疗

Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies.
PubMed 文献 · Circulation · 2018-01-01

综述讨论心力衰竭患者贫血与铁缺乏的病因、发病机制及治疗选择。贫血与铁缺乏常共存且与不良临床状态和结局相关;促红细胞生成素治疗未改善结局却增加不良事件风险。近期小型研究显示静脉铁剂可改善症状与运动能力,但长期结局与安全性数据尚缺。

要点

  • 贫血与铁缺乏常共存于心衰患者,与不良临床状态和更差结局相关。
  • 促红细胞生成素治疗心衰贫血未改善结局,且与更高不良事件风险相关。
  • 静脉铁剂在绝对或功能性铁缺乏心衰患者中改善症状与运动能力,长期数据待积累。

核心结论

  • 贫血与铁缺乏是心衰常见共病,与不良临床状态和更差结局相关,但是否为可干预的介导因素尚不完全清楚。
  • 促红细胞生成素治疗心衰贫血未改善结局且与更高不良事件风险相关。
  • 静脉铁剂在绝对或功能性铁缺乏心衰患者中改善症状与运动能力,但长期结局与安全性数据尚缺。

研究设计与样本

  • 综述,讨论心衰患者贫血与铁缺乏的病因、发病机制及治疗选择。

主要发现

  • 贫血与铁缺乏常共存,可共同或独立与不良临床状态和更差结局相关。
  • 促红细胞生成素治疗心衰贫血未改善结局,但与更高不良事件风险相关。
  • 近期小型研究发现静脉铁剂在绝对或功能性铁缺乏心衰患者中(伴或不伴贫血)改善症状与运动能力。

关键数值与推荐

  • 绝对性铁缺乏指全身总铁量减少;功能性铁缺乏指总铁量正常或增加但因储存池隔离不能满足靶组织需要。
  • 贫血合并绝对性铁缺乏时铁剂替代治疗是适当的;非贫血心衰患者绝对或功能性铁缺乏是否及如何治疗尚不清楚。

临床怎么用

  • 心衰患者应评估贫血与铁缺乏,并区分绝对性与功能性铁缺乏。
  • 对贫血合并绝对性铁缺乏者,铁剂替代治疗是适当的。
  • 非贫血心衰患者绝对或功能性铁缺乏的治疗决策需权衡症状改善与长期结局及安全性数据缺乏。

局限性

  • 静脉铁剂改善症状与运动能力的证据来自小型研究,长期结局与安全性数据尚不可得。
  • 贫血与铁缺乏是心衰严重程度的标志还是介导因素并因此应治疗,尚不完全清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia and iron deficiency are important and common comorbidities that often coexist in patients with heart failure. Both conditions, together or independently, are associated with poor clinical status and worse outcomes. Whether anemia and iron deficiency are just markers of heart failure severity or whether they mediate heart failure progression and outcomes and therefore should be treated is not entirely clear. Treatment of anemia in patients with heart failure with erythropoiesis-stimulating agents has been evaluated intensively during the past several years. Unfortunately, these agents did not improve outcomes but were associated with a higher risk of adverse events. Iron deficiency in patients with heart failure can be absolute, when total body iron is decreased, or functional, when total body iron is normal or increased but is inadequate to meet the needs of target tissues because of sequestration in the storage pool. Whereas iron replacement is appropriate in patients with anemia resulting from absolute iron deficiency, it has been unclear whether and how absolute or functional iron deficiency should be treated in nonanemic patients with heart failure. Recently, small studies found that administration of intravenous iron in patients with heart failure and absolute or functional iron deficiency with or without anemia improves symptoms and exercise capacity, but long-term outcomes and safety data are not yet available. In this review, we discuss the causes and pathogenesis of and treatment options for anemia and iron deficiency in patients with heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018. PMID: 29967232. doi:10.1161/CIRCULATIONAHA.118.030099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。